论文部分内容阅读
目的研究甜梦口服液联合氟哌噻吨美利曲辛片(黛力新)治疗脑梗死并发抑郁症的临床疗效。方法 100例脑梗死并发抑郁症患者,随机分为黛力新治疗组和联合治疗组,各50例。黛力新治疗组在常规治疗的基础上结合黛力新治疗,联合治疗组在常规治疗的基础上给予甜梦口服液联合黛力新治疗,连续治疗4周,评价两组疗效。结果治疗后联合用药组患者的HAMD评分下降幅度明显高于黛力新治疗组(P<0.05);且联合治疗组总有效率显著高于黛力新治疗组,差异具有统计学意义(P<0.05)。结论用甜梦口服液联合黛力新治疗脑梗死并发抑郁症,疗效稳定显著,并发症少,值得推广应用。
Objective To study the clinical efficacy of sweet dream oral solution combined with flupentixol and melitracen tablet (Deanxit) in the treatment of cerebral infarction complicated by depression. Methods One hundred patients with cerebral infarction complicated with depression were randomly divided into Deanxit treatment group and combination therapy group, 50 cases each. Deanxit treatment group combined with conventional treatment of Deanxit on the basis of conventional treatment, the combination therapy group on the basis of conventional treatment given sweet dream oral solution combined with Deanxit treatment, continuous treatment for 4 weeks to evaluate the efficacy of both groups. Results The decrease of HAMD score in combination group after treatment was significantly higher than that of Deanxit (P <0.05), and the total effective rate in combination group was significantly higher than that of Deanxit (P < 0.05). Conclusion Sweet dream oral solution combined Deanxit treatment of cerebral infarction complicated by depression, stable and significant effect, fewer complications, it is worth promoting the application.